PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
AIDS. Author manuscript; available in PMC 2010 October 23.
Published in final edited form as:
PMCID: PMC2761509
NIHMSID: NIHMS136686

Acute cytomegalovirus infection in Kenyan HIV-infected infants

Abstract

Objective

Cytomegalovirus (CMV) coinfection may influence HIV-1 disease progression during infancy. Our aim was to describe the incidence of CMV infection and the kinetics of viral replication in Kenyan HIV-infected and HIV-exposed uninfected infants.

Methods

HIV-1 and CMV plasma viral loads were serially measured in 20 HIV-exposed uninfected and 44 HIV-infected infants born to HIV-infected mothers. HIV-infected children were studied for the first 2 years of life, and HIV-exposed uninfected infants were studied for 1 year.

Results

CMV DNA was detected frequently during the first months of life; by 3 months of age, CMV DNA was detected in 90% of HIV-exposed uninfected infants and 93% of infants who had acquired HIV-1 in utero. CMV viral loads were highest in the 1–3 months following the first detection of virus and declined rapidly thereafter. CMV peak viral loads were significantly higher in the HIV-infected infants compared with the HIV-exposed uninfected infants (mean 3.2 versus 2.7 log10 CMV DNA copies/ml, respectively, P = 0.03). The detection of CMV DNA persisted to 7–9 months post-CMV infection in both the HIV-exposed uninfected (8/17, 47%) and HIV-infected (13/18, 72%, P = 0.2) children. Among HIV-infected children, CMV DNA was detected in three of the seven (43%) surviving infants tested between 19 and 21 months post-CMV infection. Finally, a strong correlation was found between peak CMV and HIV-1 viral loads (ρ = 0.40, P = 0.008).

Conclusion

Acute CMV coinfection is common in HIV-infected Kenyan infants. HIV-1 infection was associated with impaired containment of CMV replication.

Keywords: acute infection, cytomegalovirus, opportunistic infection, paediatric HIV, pathogenesis

Introduction

Cytomegalovirus (CMV) is a major viral cause of congenital disease globally, affecting 0.2–3% of live births in high-income and 4–14% in low-income regions [16]. CMV prevalence varies among populations according to socioeconomic conditions [7], with poorer communities having a relatively higher prevalence and earlier incidence. A recent estimate reported approximately 54% of American adults in their thirties to be CMV seropositive [8], whereas approximately 85% of Gambian infants acquire CMV before they are a year old [9].

Although CMV does not typically cause disease in healthy individuals, the virus has clinical significance during primary infection or reactivation in the immunosuppressed. CMV infection is associated with HIV-1 disease progression and mortality in adults [1013]. In the absence of HAART, patients with CD4 cell counts below 100 cells/µl are at a high risk for CMV-associated retinitis and gastrointestinal and neurologic disease [1417]. In United States cohorts, CMV coinfection has been noted in up to 40% of HIV-infected infants during the first year of life and is associated with an approximately 2.5-fold increased risk of disease progression [18,19]. In Kenya, we recently reported that the detection of maternal CMV DNA in the blood near the time of delivery was associated with a three to four times increased rate of mortality in HIV-infected infants [20]; this relationship remained significant after controlling for other strong predictors of infant mortality, including maternal CD4 cell count, CD4 cell percentage, HIV-1 RNA viral load and maternal death.

If CMV presents a significant risk factor for HIV-1 disease progression, its impact may be particularly important in African children where both viruses are commonly acquired in infancy [2,21]. In order to understand the mechanisms that underlie the relationship between CMV coinfection and rapid HIV-1 disease progression, it is first necessary to determine the incidence of CMV infection among HIV-infected infants and to describe its natural history. Although risk factors associated with vertical CMV transmission are well defined, very few studies [22,23] have measured CMV replication quantitatively in infants, and only one longitudinal study [24] has described infant CMV viral load in the setting of HIV-1. The purpose of our study was to describe the incidence and timing of CMV infection and the kinetics of CMV viral replication in HIV-infected and HIV-exposed uninfected Kenyan infants.

Methods

Participants and study design

Study protocols were approved by the Ethics Review Committee of Kenyatta National Hospital and the Institutional Review Board of the University of Washington. A cohort of infants born to HIV-infected women was used to study acute infant CMV infection. As part of a larger cohort study of perinatal HIV-1 transmission, HIV-infected pregnant women were recruited in Nairobi between 1999 and 2003 [25,26].

The women received short-course zidovudine for prevention of HIV-1 transmission [27]. Mothers and infants were followed during pregnancy, delivery and for 1–2 years postpartum, during which time serial blood specimens were obtained in pregnancy, at delivery and months 1, 3, 6, 9, 12, 15, 18, 21 and 24 postpartum. Sixty-four infants were selected from the larger cohort based on survival to at least 3 months of age and the availability of a plasma specimen by 1 month of age. Infants were followed until death or exit from the study at 1 year (HIV-exposed uninfected) or 2 years of life (HIV infected).

HIV-1 diagnosis and quantification

Diagnosis of infant HIV-1 infection was made using PCR amplifying HIV-1 gag DNA from dried blood spotted onto filter paper as previously described [28]. HIV-1 RNA viral loads were measured using the Gen-Probe assay [29]. HIV-1 infection was defined as the detection of either HIV-1 DNA or RNA; the timing of HIV-1 infection was estimated as the midpoint between the last HIV-negative test and the first HIV-1-positive test. Infants were grouped according to first HIV-1 detection: in utero (within 48 h of birth, n = 15), peripartum (uninfected at birth, infected at 1 month, n = 16) or late (infected after 1 month, n = 13). In the ‘late’ infection group, estimated infection times were: 2 months (six infants), 2.5 months (one infant), 4.5 months (one infant), 5 months (one infant), 6 months (one infant), 7.5 months (two infants) and 10.5 months (one infant). Peak and set-point HIV-1 viral load were used to describe the dynamics and control of HIV-1 replication during early infection. We defined peak HIV-1 viral load as the highest measurement in the first 6 months after infection; HIV-1 set-point was defined as the first viral load observation measured at least 6 weeks after the peak [30].

Cytomegalovirus viral load measurements

Cord blood was used to diagnose in utero CMV transmission. Following delivery of the placenta, umbilical cords were clamped in two locations and swabbed to remove maternal blood. Blood was then collected with a syringe and transferred to EDTA Vacutainer tubes (Becton Dickinson Diagnostics, Franklin Lakes, New Jersey, USA). At all other time-points, venous blood was collected. Viral nucleic acids were extracted from 50–200 µl of plasma using the Qiagen UltraSens virus extraction kit (Qiagen, Valencia, California, USA). Quantitative PCR was used to detect the glycoprotein B gene [31], and copy number was determined with the aid of a standard curve derived from known quantities of cloned amplicon DNA. Each individual’s viral load was determined by calculating the mean of three replicate reactions. The lower limit of detection was one copy per reaction. Negative (no DNA detection) and indeterminate (less than one copy per reaction) PCR assays were not included in calculations of median or peak viral load and were categorized as negative for CMV DNA.

Indeterminate PCR assays were assigned a value equivalent to the midpoint between the limit of detection and zero for longitudinal modelling but were not included in the calculation of peak CMV viral load. Peak CMV viral load was defined as the highest viral load observed for each CMV-infected infant during the first 6 months after infection.

Statistical analysis

STATA SE version 9 for Macintosh (STATA Corp., College Station, Texas, USA) was used for the statistical analysis. Viral loads were base 10 log-transformed (log10). The t-test was used to compare continuous variables, and Fisher’s exact tests were used to compare proportions. S-Plus (S-Plus 2000; Mathsoft, Inc., Seattle, Washington, USA) was used to create non-parametric smoothers for CMV DNA over time using Freidman’s super smoother. Area under the curve (AUC) for each child’s log viral load from 3 to 12 months of life was estimated using SPSS version 15.0 (SPSS Inc., Chicago, Illinois, USA). The t-test was used to compare mean AUC of longitudinal viral loads between groups of infants. Spearman’s rank correlation coefficient was used to describe the correlation between HIV-1 and CMV viral load. All P values reported are for two-tailed tests.

Results

Patient characteristics

Median maternal age at enrolment was 25 years [interquartile range (IQR) = 22–29 years], and median parity was 1 (IQR = 1–2). Characteristics of the infants studied are shown in Table 1. HIV-infected infants were followed for 24 months; infants with no HIV-1 detection exited the study at 12 months. As previously reported, HIV-1 viral loads and mortality were very high among HIV-infected infants in the cohort, and there were 23 infant deaths among the selected patients [30,32].

Table 1
Patient characteristics.

Cytomegalovirus acquisition occurs primarily during the first 3 months of life in Kenyan HIV-exposed infants

HIV-1 and CMV viral loads were measured serially in 44 HIV-infected and 20 HIV-exposed uninfected infants (390 concurrent HIV-1 and CMV viral load measurements). Plasma specimens were available for CMV DNA assessment at birth from 51 infants and by 1 month of age from all 64 infants. CMV DNA was detected in the cord blood plasma of 29% (4/14) of HIV-infected newborns and 2.7% (1/37) of infants who were HIV-1 RNA negative at birth (P = 0.02). None of the infants with detection of CMV DNA at birth had overt clinical evidence of congenital CMV disease.

In both the HIV-infected and HIV-exposed uninfected infants, the majority of CMV infections occurred during the first 3 months of life (Table 2). By 3 months of age, CMV DNA had been detected in 90% of HIV-exposed uninfected infants, 93% of infants who were HIV infected at birth, 75% of infants who acquired HIV-1 peripartum and 85% of infants who acquired HIV-1 infection through late breast milk transmission. Only three infants in the study group had no CMV DNA detection during follow-up: two of these infants completed follow-up and one infant died at 3.5 months of age.

Table 2
Cytomegalovirus detection in children grouped by mode of HIV-1 acquisition.

Cytomegalovirus DNA detection in HIV-unexposed infants

A small group of HIV-uninfected women and their infants (n = 13) with similar demographics to the larger study were examined to determine the prevalence of CMV in the absence of HIV-1. Of 13 HIV-negative women screened at delivery, 13 (100%) were CMV seropositive but none had detectable CMV DNA. Over 6 months of follow-up, CMV DNA was detected in six of 13 (46%) infants born to these mothers.

Cytomegalovirus DNA is commonly detected in plasma during the first 1–2 years of infection

CMV DNA viral loads were measured longitudinally during follow-up. Although there was heterogeneity between individual infants during acute CMV infection, the overall pattern was a peak at the first detection of CMV or at the following measurement, followed by a decline (Fig. 1). Among the group of infants with late breast milk acquisition of HIV-1 who acquired CMV before HIV-1, secondary peaks in CMV viral load were sometimes observed concurrent to the first detection of HIV-1 RNA (one infant who became CMV DNA positive at 1 month and three infants who became CMV positive at 3 months).

Fig. 1
The kinetics of cytomegalovirus viral load during acute infection in HIV-exposed infants

Infant HIV-1 infection and cytomegalovirus replication

To determine whether HIV-1 infection compromised control of CMV replication, we compared peak CMV viral loads between HIV-infected and HIV-exposed uninfected infants (Fig. 2a). To avoid assessing cases in which infants acquired HIV-1 several months after having acquired CMV, we excluded the late HIV-infected infants in this comparison. We detected higher peak CMV viral loads among the infants with HIV-1 infection [mean 3.2, standard error (SE) 0.15] compared with the HIV-exposed uninfected infants (2.7 SE, 0.15 log10 CMV D-NA copies/ml, P = 0.03).

Fig. 2
HIV-1 infection and cytomegalovirus replication

We also examined control of CMV replication by comparing the decline in CMV viral loads between HIV-infected and HIV-exposed uninfected infants (Fig. 2b). To control for differential timing of CMV and HIV infection, we restricted the analysis to children who first became CMV DNA positive at 3 months of age and excluded the late HIV-1 acquisition group. In both HIV-infected and HIV-exposed uninfected infants, CMV viral load declined steadily from infection to 12 months of age. However, the mean AUC for CMV replication had a trend to be higher among the HIV-infected than the HIV-exposed uninfected group (P = 0.09), suggesting a trend for more rapid reduction of CMV viral load in the HIV-exposed uninfected infants.

There was also a significant correlation between peak CMV and peak HIV-1 viral load (correlation coefficient ρ= 0.40, P = 0.008, Fig. 2c). Peak CMVand HIV-1 set-point viral load were also correlated in the 37 HIV-infected infants with HIV-1 set-point measurements (ρ = 0.34, P = 0.04, data not shown).

Persistence of cytomegalovirus DNA replication during the 1–2-year postinfection period

Although CMV viral loads were typically lower in the months following acute CMV infection, CMV DNA was commonly detected at several months after infection in both the HIV-infected and HIV-exposed uninfected infants (Table 3). As infants were evaluated every 3 months, we examined CMV DNA detection in 3-monthly intervals after first CMV DNA detection. Infants were counted once in each time interval; if an infant was tested more than once within the interval (five infants), only the test result at the later visit is reported. Between 7 and 9 months after the first detection of CMV DNA, CMV DNA was detected in 13 of 18 (72%) HIV-infected and eight of 17 (47%) HIV-exposed uninfected infants (P = 0.2). Among the HIV-infected infants, who were followed for an additional year, CMV DNA was detected in seven of 10 (70%) surviving infants who were tested between 13 and 15 months post-CMV infection and in three of seven (43%) infants tested between 19 and 21 months post-CMV infection.

Table 3
Detection of cytomegalovirus DNA in HIV-exposed infants following acute infection.

Discussion

The current study highlights the extremely high incidence of CMV infection in Kenyan HIV-infected and exposed infants. CMV was almost universally acquired during the first year of life in the cohort, irrespective of HIV-1 status. HIV-1 infection altered the kinetics of CMV replication; CMV levels peaked at higher levels and had a trend to decline more slowly in HIV-infected infants. We found persistent detection of CMV DNA to be common in both HIV-1-infected and HIV-exposed uninfected infants in the 7–12-month postinfection period, suggesting incomplete containment of CMV replication by both HIV-infected and HIV-exposed uninfected infants. Finally, peak CMV and HIV-1 viral loads were highly correlated, suggesting that similar factors may affect the replication of both viruses.

CMV was acquired rapidly in this cohort. The cumulative incidence of CMV we observed at 6 months of age (81–93%) is higher than has been documented in healthy Gambian children (~53%) [2] and HIV-1-exposed (~15–20%) and HIV-infected children (~30–40%) in the United States cohorts of similar age [18,33]. Early CMV incidence in our cohort was probably due to the combination of maternal HIV-1 infection and prevalent breastfeeding and is likely to reflect infant CMV prevalence in similar African cohorts of breastfeeding HIV-infected mothers. We also observed a high frequency of in utero CMV transmission in the cohort. Increased rates of congenital CMV have previously been noted in HIV-infected newborns (~4–20%) [19]. In the current study, newborns with HIV-1 infection were more likely to have CMV at birth compared with HIV-exposed uninfected newborns. Several mechanisms may explain this observation; HIV-infected mothers who transmitted HIV-1 in utero would be expected to be more immunosuppressed, and therefore at increased risk of CMV transmission. Immunosuppression during foetal HIV-1 infection may result in a higher risk of CMV acquisition in utero. Alternately, foetal CMV coinfection may facilitate HIV-1 acquisition in utero.

Serial CMV viral load measurements enabled us to describe the kinetics of CMV replication in HIV-infected and HIV-exposed uninfected infants. We observed a rapid decline in CMV viral load following its first detection, followed by persistent or transient CMV detection. Low-level systemic CMV replication continued for many months after infection; CMV DNA could be detected in approximately 44% of the HIV-infected children tested after 16–18 months of infection. This frequency of detection is somewhat higher than that observed by Revello et al. [23] who measured CMV in the lymphocytes of approximately 25% of congenitally infected infants at more than 4 months of age. This long period of systemic CMV replication contrasts with reports from adults undergoing primary CMV infection, in which CMV DNA typically becomes undetectable in blood 6 months after infection [34,35]. This extended period of CMV replication may be explained by differences in cellular immune responses generated by infants and adults. Although infant CD8 T cells appear to be similar to adult T cells in their ability to expand and secrete interferon-gamma (IFNγ) [36], the infant CD4 cell response to CMV appears to be qualitatively and quantitatively different. Markedly lower T-helper cell 1 (Th1)-type CD4 cell responses have been reported in children compared with adults [37], and the clearance of viruria occurs concurrently with an increase in CMV-specific lymphoproliferation responses [38,39]. HIV-induced dysregulation of immune responses and destruction of CD4 T cells may further contribute to the preexisting age-related deficit in infant CMV-specific CD4 cell responses. Although it is beyond the scope of our current data to draw such conclusions, one may speculate that HIV-induced impairment of infant CMV-specific CD4 cell responses may contribute to the elongated period of systemic CMV replication observed in our study.

HIV infection was associated with higher peak CMV viral loads and a trend for a slower reduction in CMV viral load during the postacute phase. Unfortunately, we were unable to examine the relationship between CD4 cell counts and CMV viral load, but we speculate that impaired containment of CMV during infancy is most likely due to immunosuppression. Although overt signs of CMV disease were not noted in any of the children under study, we cannot rule out a contribution of CMV to the high rate of infant mortality in this cohort. CMV can cause a varied spectrum of diseases, including gastrointestinal illness, which was a major cause of death in the cohort [32].

In our study, peak CMVand HIV-1 viral load were highly correlated. In HIV-1-infected adults, correlations between CMV and HIV-1 viral load have been reported in the blood [12] and breast milk [40], and HIV-1 shedding in the cervix is more frequently detected if CMV DNA is detected in the same compartment [41]. In vitro studies have shown interactions between the viruses on a cellular level [13], and it is likely that local inflammation also fuels the replication of both viruses. Although the ex vivo data collected by us and others suggest an association between CMV and HIV-1 replication, it is at present impossible to infer a causal relationship or the direction of any such relationship. In the adult studies, the appearance of CMV in the blood is likely a result of reactivation of latent infection during severe immunosuppression, whereas the infants in our study were undergoing an acute CMV infection during periods of very high HIV-1 viraemia. The correlation between peak HIV-1 and CMV viral load likely suggests that similar host factors may affect the containment of both viruses.

Our study has some limitations. Infant urine specimens were not collected in the base cohort study, so virus culture from urine was not available as the gold standard method for diagnosing in utero CMV transmission. It is thus possible that we have underestimated the true incidence of in utero CMV transmission. Additionally, using HIV-1-exposed uninfected infants as controls likely underestimates the effects of HIV-1 infection on CMV containment. This group provided a convenient comparison group for our study, but HIV-exposed uninfected children are known to differ from HIV-unexposed children in terms of immunological development, morbidity and mortality [42]. Finally, we were unable to examine the effect of CMV on HIV-1 viral replication or mortality due to the very high incidence of CMV. A prospective trial designed with greater statistical power would be necessary to address the relationship between CMV infection, CMV viral load and mortality in HIV-infected Kenyan infants.

Conclusion

Acute concurrent CMV and HIV-1 infection occurs frequently in children born to HIV-infected Kenyan women. A high incidence of coinfection, impaired CMV containment, persistent CMV DNA detection and a correlation between CMV and HIV-1 peak viral loads suggest that CMV may play an important role in paediatric HIV-1 in this region. These results emphasize the urgent need for a CMV vaccine in sub-Saharan Africa. A recent clinical trial [43] of a recombinant glycoprotein B vaccine reported 50% efficacy against CMV infection in CMV-seronegative women, offering encouragement for the control of CMV infection in Kenya and other resource-poor settings.

Acknowledgements

The authors acknowledge the contributions of the Cytotoxic T Lymphocyte (CTL) Study clinical, laboratory and data teams at the University of Nairobi and Kenyatta National Hospital. HIV filter paper assays were performed by Dana DeVange Panteleeff [Fred Hutchinson Cancer Research Center (FHCRC)], and Kenneth Tapia (University of Washington) assisted with the analyses.

J.S., T.D., A.I., V.E., S.R.-J. and G.J.-S. conceived and designed the nested CMV study, and G.J.-S., B.R., E.O., D.M.-N. and B.L.-P. conceived and designed the parent study, which was designed to examine the correlates of maternal and infant disease/progression and mortality. J.O. and S.E. participated in the design of the virology assays and interpreted the virologic data. B.R. and J.S. performed the statistical analyses. All authors have participated in manuscript revisions and approved the final version.

This publication was made possible by grant numbers R01 HD-23412 and 1 K24 HD054314 from the United States National Institutes of Child Health and Disease (NICHD), principal investigator G.C.J.-S. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NICHD. Additional funding was provided by the Medical Research Council (MRC) grant to the Human Immunology Unit of the Weatherall Institute of Molecular Medicine. J.A.S. was supported by the University of Washington STD and AIDS Research Training Program, T32 AI007140 from the National Institutes of Health (NIH) and United States Public Health Service (USPHS). J.A.S., B.L.L.-P. and E.M.-O. were scholars in the AIDS International Training and Research Program, NIH Research Grant D43 TW000007, funded by the Fogarty International Center and the Office of Research on Women’s Health. G.C.J.-S. was supported in part by a Pediatric AIDS Foundation Elizabeth Glaser Scientist Award. V.E.E. is funded by a grant from the MRC Centre for Clinical Virology. The funding sources were not involved in the analyses or interpretation of data.

Footnotes

There are no conflicts of interest.

Data contained in this manuscript were presented orally at the Dominique Dormont International Conference: Maternal chronic viral infections transmitted to the infants

References

1. Stagno S, Reynolds DW, Huang ES, Thames SD, Smith RJ, Alford CA. Congenital cytomegalovirus infection. N Engl J Med. 1977;296:1254–1258. [PubMed]
2. Bello C, Whittle H. Cytomegalovirus infection in Gambian mothers and their babies. J Clin Pathol. 1991;44:366–369. [PMC free article] [PubMed]
3. Schlesinger Y, Reich D, Eidelman AI, Schimmel MS, Hassanin J, Miron D. Congenital cytomegalovirus infection in Israel: screening in different subpopulations. Isr Med Assoc J. 2005;7:237–240. [PubMed]
4. Sohn YM, Park KI, Lee C, Han DG, Lee WY. Congenital cyto-megalovirus infection in Korean population with very high prevalence of maternal immunity. J Korean Med Sci. 1992;7:47–51. [PMC free article] [PubMed]
5. Larke RP, Wheatley E, Saigal S, Chernesky MA. Congenital cytomegalovirus infection in an urban Canadian community. J Infect Dis. 1980;142:647–653. [PubMed]
6. Zhang XW, Li F, Yu XW, Shi XW, Shi J, Zhang JP. Physical and intellectual development in children with asymptomatic congenital cytomegalovirus infection: a longitudinal cohort study in Qinba mountain area, China. J Clin Virol. 2007;40:180–185. [PubMed]
7. Stagno S, Pass RF, Cloud G, Britt WJ, Henderson RE, Walton PD, et al. Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome. JAMA. 1986;256:1904–1908. [PubMed]
8. Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43:1143–1151. [PubMed]
9. Kaye S, Miles D, Antoine P, Burny W, Ojuola B, Kaye P, et al. Virological and immunological correlates of mother-to-child transmission of cytomegalovirus in The Gambia. J Infect Dis. 2008;197:1307–1314. [PubMed]
10. Webster A, Lee CA, Cook DG, Grundy JE, Emery VC, Kernoff PB, Griffiths PD. Cytomegalovirus infection and progression towards AIDS in haemophiliacs with human immunodeficiency virus infection. Lancet. 1989;2:63–66. [PubMed]
11. Sabin CA, Devereux HL, Clewley G, Emery VC, Phillips AN, Loveday C, et al. Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia. J Infect Dis. 2000;181:1800–1803. [PubMed]
12. Spector SA, Hsia K, Crager M, Pilcher M, Cabral S, Stempien MJ. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol. 1999;73:7027–7030. [PMC free article] [PubMed]
13. Griffiths PD. CMV as a cofactor enhancing progression of AIDS. J Clin Virol. 2006;35:489–492. [PubMed]
14. Drew WL. Nonpulmonary manifestations of cytomegalovirus infection in immunocompromised patients. Clin Microbiol Rev. 1992;5:204–210. [PMC free article] [PubMed]
15. Gerard L, Leport C, Flandre P, Houhou N, Salmon-Ceron D, Pepin JM, et al. Cytomegalovirus (CMV) viremia and the CD4+ lymphocyte count as predictors of CMV disease in patients infected with human immunodeficiency virus. Clin Infect Dis. 1997;24:836–840. [PubMed]
16. Gallant JE, Moore RD, Richman DD, Keruly J, Chaisson RE. Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. J Infect Dis. 1992;166:1223–1227. [PubMed]
17. Salmon-Ceron D, Mazeron MC, Chaput S, Boukli N, Senechal B, Houhou N, et al. Plasma cytomegalovirus DNA, pp65 anti-genaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy. AIDS. 2000;14:1041–1049. [PubMed]
18. Kovacs A, Schluchter M, Easley K, Demmler G, Shearer W, La Russa P, et al. Cytomegalovirus infection and HIV-1 disease progression in infants born to HIV-1-infected women. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection Study Group. N Engl J Med. 1999;341:77–84. [PubMed]
19. Doyle M, Atkins JT, Rivera-Matos IR. Congenital cytomegalovirus infection in infants infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1996;15:1102–1106. [PubMed]
20. Slyker JA, Lohman-Payne BL, Rowland-Jones SL, Otieno P, Maleche-Obimbo E, Richardson B, et al. The detection of cytomegalovirus DNA in maternal plasma is associated with mortality in HIV-1-infected women and their infants. AIDS. 2009;23:117–124. [PMC free article] [PubMed]
21. van der Sande MA, Kaye S, Miles DJ, Waight P, Jeffries DJ, Ojuola OO, et al. Risk factors for and clinical outcome of congenital cytomegalovirus infection in a peri-urban West-African birth cohort. PLoS ONE. 2007;2:e492. [PMC free article] [PubMed]
22. Lanari M, Lazzarotto T, Venturi V, Papa I, Gabrielli L, Guerra B, et al. Neonatal cytomegalovirus blood load and risk of sequelae in symptomatic and asymptomatic congenitally infected new-borns. Pediatrics. 2006;117:e76–e83. [PubMed]
23. Revello MG, Zavattoni M, Baldanti F, Sarasini A, Paolucci S, Gerna G. Diagnostic and prognostic value of human cytomegalovirus load and IgM antibody in blood of congenitally infected newborns. J Clin Virol. 1999;14:57–66. [PubMed]
24. Boriskin YS, Sharland M, Dalton R, duMont G, Booth JC. Viral loads in dual infection with HIV-1 and cytomegalovirus. Arch Dis Child. 1999;80:132–136. [PMC free article] [PubMed]
25. John-Stewart GC, Mbori-Ngacha D, Payne BL, Farquhar C, Richardson BA, Emery S, et al. HIV-1-specific cytotoxic T lymphocytes and breast milk HIV-1 transmission. J Infect Dis. 2009;199:889–898. [PMC free article] [PubMed]
26. Lohman BL, Slyker JA, Richardson BA, Farquhar C, Mabuka JM, Crudder C, et al. Longitudinal assessment of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon responses during the first year of life in HIV-1-infected infants. J Virol. 2005;79:8121–8130. [PMC free article] [PubMed]
27. Shaffer N, Chuachoowong R, Mock PA, Bhadrakom C, Siriwasin W, Young NL, et al. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial. Lancet. 1999;353:773–780. [PubMed]
28. DeVange Panteleeff D, John G, Nduati RW, Mbori-Ngacha DA, Richardson BA, Kreiss JK, Overbaugh J. Rapid method for screening dried blood samples on filter paper for HIV type 1 DNA. J Clin Microbiol. 1999;37:350–353. [PMC free article] [PubMed]
29. Emery S, Bodrug S, Richardson BA, Giachetti C, Bott MA, Panteleeff D, et al. Evaluation of performance of the Gen-Probe human immunodeficiency virus type 1 viral load assay using primary subtype A, C, and D isolates from Kenya. J Clin Microbiol. 2000;38:2688–2695. [PMC free article] [PubMed]
30. Maleche-Obimbo E, Wamalwa D, Richardson B, Mbori-Ngacha D, Overbaugh J, Emery S, et al. Pediatric HIV-1 in Kenya: pattern and correlates of viral load and association with mortality. J Acquir Immune Defic Syndr. 2009;51:209–215. [PMC free article] [PubMed]
31. Mattes FM, Hainsworth EG, Hassan-Walker AF, Burroughs AK, Sweny P, Griffiths PD, Emery VC. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis. 2005;191:89–92. [PubMed]
32. Obimbo EM, Mbori-Ngacha DA, Ochieng JO, Richardson BA, Otieno PA, Bosire R, et al. Predictors of early mortality in a cohort of human immunodeficiency virus type 1-infected African children. Pediatr Infect Dis J. 2004;23:536–543. [PMC free article] [PubMed]
33. Chandwani S, Kaul A, Bebenroth D, Kim M, John DD, Fidelia A, et al. Cytomegalovirus infection in human immunodeficiency virus type 1-infected children. Pediatr Infect Dis J. 1996;15:310–314. [PubMed]
34. Zanghellini F, Boppana SB, Emery VC, Griffiths PD, Pass RF. Asymptomatic primary cytomegalovirus infection: virologic and immunologic features. J Infect Dis. 1999;180:702–707. [PubMed]
35. Revello MG, Zavattoni M, Sarasini A, Percivalle E, Simoncini L, Gerna G. Human cytomegalovirus in blood of immunocompetent persons during primary infection: prognostic implications for pregnancy. J Infect Dis. 1998;177:1170–1175. [PubMed]
36. Marchant A, Appay V, Van Der Sande M, Dulphy N, Liesnard C, Kidd M, et al. Mature CD8(+) T lymphocyte response to viral infection during fetal life. J Clin Invest. 2003;111:1747–1755. [PMC free article] [PubMed]
37. Tu W, Chen S, Sharp M, Dekker C, Manganello AM, Tongson EC, et al. Persistent and selective deficiency of CD4+ T cell immunity to cytomegalovirus in immunocompetent young children. J Immunol. 2004;172:3260–3267. [PubMed]
38. Reynolds DW, Dean PH, Pass RF, Alford CA. Specific cell-mediated immunity in children with congenital and neonatal cytomegalovirus infection and their mothers. J Infect Dis. 1979;140:493–499. [PubMed]
39. Pass RF, Stagno S, Britt WJ, Alford CA. Specific cell-mediated immunity and the natural history of congenital infection with cytomegalovirus. J Infect Dis. 1983;148:953–961. [PubMed]
40. Gantt S, Carlsson J, Shetty AK, Seidel KD, Qin X, Mutsvangwa J, et al. Cytomegalovirus and Epstein–Barr virus in breast milk are associated with HIV-1 shedding but not with mastitis. AIDS. 2008;22:1453–1460. [PMC free article] [PubMed]
41. Lurain NS, Robert ES, Xu J, Camarca M, Landay A, Kovacs AA, Reichelderfer PS. HIV type 1 and cytomegalovirus coinfection in the female genital tract. J Infect Dis. 2004;190:619–623. [PMC free article] [PubMed]
42. Filteau S. The HIV-exposed, uninfected African child. Trop Med Int Health. 2009;14:276–287. [PubMed]
43. Pass RF, Zhang C, Evans A, Simpson T, Andrews W, Huang ML, et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med. 2009;360:1191–1199. [PMC free article] [PubMed]